NICE rejects again Imbruvica (ibrutinib) to treat Mantle Cell Lymphoma but recommends the drug to treat Waldenstrom's macroglobulinaemia.- Janssen Biotech.
The National Institute for Health and Care Excellence (NICE) in draft guidance has not recommended Imbruvica (ibrutinib) to treat Mantle Cell Lymphoma as the proposal from Janssen was not cost effective. However the committee said that they would consider a proposal to include the drug in the new version of the Cancer Drugs Fund (CDF) if found cost effective.
NICE agreed to recommend Imbruvica by inclusion in the CDF to treat Waldenstrom's macroglobulinaemia for patients who had at least one previous therapy or as first line therapy where chemo- immunotherapy is unsuitable.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.